细胞解离胰蛋白酶-EDTA溶液市场 - 全球产业规模、份额、趋势、机会、预测：按类型、应用、地区和竞争格局划分，2021-2031年

全球用于细胞分离的胰蛋白酶-EDTA溶液市场预计将从2025年的20.2亿美元成长到2031年的29.2亿美元，复合年增长率达到6.33%。

胰蛋白酶-EDTA 是一种基础酶试剂，用于细胞培养流程中，透过切割肽键和螯合整合素来支持阳离子，将贴壁细胞从基材分离。这个市场成长的主要驱动力是生物製药生产的规模化，特别是单株抗体和疫苗的生产，以及再生医学的快速发展，后者需要持续的细胞收穫。为了支持如此活跃的产业活动，根据国际细胞与基因治疗学会 (ISCT) 统计，截至 2024 年，全球共有 3063 种细胞和基因疗法处于开发平臺，因此需要大量可靠的细胞分离试剂来实现高效的上游工程加工。

儘管市场成长迅速，但仍面临许多挑战，包括胰蛋白酶对高度敏感的原代细胞株的潜在细胞毒性，以及对动物性成分的严格监管。这些担忧促使企业越来越倾向于选择重组或非酵素製剂，对传统上占据主导地位的猪源性胰蛋白酶-EDTA製剂构成挑战。因此，製造商被迫不断创新，以满足现代治疗药物生产所需的严格安全标准。

市场驱动因素

全球胰蛋白酶-EDTA市场的主要驱动力是生物製药和生物製药生产的快速扩张。随着製药公司积极拓展研发管线以应对复杂的疾病，生物製品生产和药物筛检所需的细胞培养工作量呈现爆炸性成长。上游工程的强化需要稳定的酵素试剂供应，以确保高效的细胞分离和传代。根据国际药品製造商协会联合会（IFPMA）于2024年12月发布的《2024年事实与数据》报告，全球药物开发平臺中处于不同研发阶段的药物超过12,700种，如此庞大的工作量导致中先导工厂和研究机构对分离液的需求持续增长。

同时，干细胞疗法和再生医学的蓬勃发展正在为市场创造一个独特的、高成长的领域。这些先进治疗方法高度依赖间质干细胞等黏附依赖性细胞，而这些细胞需要经过精确的酵素处理才能在收穫时保持活性。该领域强劲的资金实力正在加速临床应用。根据再生医学联盟于2025年1月发布的《产业趋势简报》，2024年细胞和基因治疗领域的投资成长了30%。这笔资金流入正在支持从研究到临床试验的过渡，并得益于有利的法规环境，包括美国食品药物管理局（FDA）药物评估与研究中心在2024年核准的50种新药。

市场挑战

由于担心传染性病原体和病毒污染，对动物性成分（尤其是猪胰蛋白酶）的严格监管成为市场准入的主要障碍。监管机构正在执行严格的安全通讯协定，以防止外来物质进入生物製药生产过程，并要求进行广泛的病毒去除测试和记录。这种监管显着增加了合规负担，提高了製造商的营运复杂性和成本。因此，这些严格的要求阻碍了传统配方的市场准入和扩充性生产，延缓了供应链，并影响了这些关键试剂的稳定供应。

这种强化品管的环境直接影响市场的稳定性和成长。根据美国药典（USP）2024年药品短缺年度报告，上年度药品供应链中的产品停产率上升了40%，这一趋势主要受生产复杂性和品质监控挑战的影响。这些数据凸显了监管压力和相关的营运复杂性如何阻碍生产的连续性。在胰蛋白酶-EDTA市场，儘管细胞治疗领域的需求不断增长，但这些障碍限制了整体市场成长，并阻碍了动物性解决方案的顺利推广。

市场趋势

在产业对高通量效率和可重复性需求的驱动下，胰蛋白酶处理通讯协定与自动化液体处理系统的整合正在显着改变市场模式。实验室正从手动分离转向机器人平台，以最大限度地减少人为误差并标准化细胞传代，这需要黏度一致的酶製剂和专用包装，以确保与机器人介面的兼容性。这种向自动化工作流程的转变凸显了对能够在复杂仪器生态系统中无缝运作的可靠分离试剂的需求。根据Benchling于2024年11月发布的《2024年生物製药技术趋势报告》，83%的领先生物製药公司已经实现了至少部分实验室流程的自动化，这凸显了关键的营运转变，而这种转变需要相容的酵素解决方案。

同时，类器官解离和3D细胞培养的应用领域正明显超越传统的单层培养技术。随着研究人员在药物筛检中优先考虑生理相关模型，对能够有效穿透球状体和类器官内部緻密细胞外基质且不损害细胞活性的解离剂的需求日益增长。这项技术需求推动了市场对专门用于精细解离三维组织结构的最佳化酵素溶液的需求。例如，西奈健康研究所于2024年3月发布新闻稿宣布，已获得1000万美元投资，用于建立一个最先进的组织工程平台，专门用于开发复杂的人类类器官，以支持疾病研究和药物发现。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：胰蛋白酶-EDTA细胞解离溶液的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（0.25%溶液，0.05%溶液）
  • 依应用领域（胰岛素生产、疫苗生产、细胞培养等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美细胞解离用胰蛋白酶-EDTA溶液市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲细胞解离用胰蛋白酶-EDTA溶液市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区胰蛋白酶-EDTA细胞解离溶液的市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲细胞解离用胰蛋白酶-EDTA溶液的市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲细胞解离用胰蛋白酶-EDTA溶液的市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球胰蛋白酶-EDTA溶液细胞解离市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc
• Lonza Group Ltd
• Merck KGa
• Sartorius AG
• Biosera Europe
• Irvine Scientific
• Chargen Life Sciences LLP
• ScienCell Research Laboratories, Inc.
• STEMCELL Technologies Canada Inc.
• PromoCell GmbH

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Trypsin-EDTA Solution for Cell Dissociation Market is projected to expand from USD 2.02 Billion in 2025 to USD 2.92 Billion by 2031, achieving a CAGR of 6.33%. As a fundamental enzymatic reagent, Trypsin-EDTA is utilized in cell culture workflows to detach adherent cells from substrates by cleaving peptide bonds and chelating integrin-supporting cations. This market growth is primarily driven by the increasing scale of biopharmaceutical manufacturing, especially for monoclonal antibodies and vaccines, as well as the rapid advancement of regenerative medicine which requires consistent cell harvesting. Supporting this high level of industrial activity, data from the International Society for Cell & Gene Therapy indicates that in 2024, there were 3,063 cell and gene therapies in the global development pipeline, a landscape that necessitates substantial volumes of reliable cell dissociation agents for efficient upstream processing.

Despite this growth, the market faces significant hurdles regarding the potential cytotoxicity of trypsin towards sensitive primary cell lines and the strict regulatory scrutiny surrounding animal-derived components. These concerns are fostering a strategic preference for recombinant or non-enzymatic alternatives, posing a challenge to the traditional dominance of porcine-sourced Trypsin-EDTA formulations. Consequently, manufacturers are compelled to innovate continuously to uphold the rigorous safety standards required for modern therapeutic production.

Market Driver

The primary catalyst propelling the global trypsin-EDTA market is the rapid expansion of biopharmaceutical and biologics manufacturing. As pharmaceutical companies aggressively scale their pipelines to address complex pathologies, the volume of cell culture operations required for biological production and drug screening has surged. This intensification of upstream processing demands consistent supplies of enzymatic reagents to ensure efficient cell detachment and passage. According to the 'Facts & Figures 2024' report by the International Federation of Pharmaceutical Manufacturers & Associations in December 2024, the global pharmaceutical pipeline contained over 12,700 medicines in various stages of development, a massive workload that translates into sustained consumption of dissociation solutions across pilot plants and research laboratories.

Concurrently, the surge in stem cell therapy and regenerative medicine development is creating a specialized, high-growth avenue for the market. These advanced modalities rely heavily on anchorage-dependent cells, such as mesenchymal stem cells, which demand precise enzymatic treatment to maintain viability during harvesting. The sector's robust financial health is accelerating clinical translation; according to the Alliance for Regenerative Medicine's 'State of the Industry Briefing' in January 2025, investment in the cell and gene therapy sector increased by 30% in 2024. This influx of capital supports the transition from bench to bedside, further bolstered by a favorable regulatory environment where the FDA's Center for Drug Evaluation and Research approved 50 novel drugs in 2024.

Market Challenge

The market is significantly impeded by strict regulatory scrutiny regarding animal-derived components, specifically porcine-sourced trypsin, due to concerns over transmissible agents and viral contamination. Regulatory bodies enforce rigorous safety protocols to prevent the introduction of adventitious agents into biopharmaceutical workflows, necessitating extensive viral clearance testing and documentation. This oversight creates a substantial compliance burden, elevating operational complexity and costs for manufacturers. Consequently, these stringent requirements act as a barrier to entry and scalability for traditional formulations, slowing the supply chain and causing friction in the reliable distribution of these essential reagents.

This environment of heightened quality control directly impacts market stability and growth. According to the U.S. Pharmacopeia's 2024 Annual Drug Shortages Report, product discontinuations in the pharmaceutical supply chain rose by 40% during the preceding year, a trend heavily influenced by manufacturing complexities and quality oversight challenges. This statistic underscores how regulatory pressures and the resulting operational intricacies can disrupt production continuity. For the Trypsin-EDTA market, such hurdles limit the seamless expansion of animal-derived solutions, restricting overall market growth despite increasing demand from the cell therapy sector.

Market Trends

The integration of trypsinization protocols into automated liquid handling systems is significantly reshaping the market, driven by the industry's need for high-throughput efficiency and reproducibility. Laboratories are increasingly replacing manual dissociation with robotic platforms to minimize human error and standardize cell passage, necessitating enzyme formulations with consistent viscosity and specialized packaging for robotic interface compatibility. This shift toward automated workflows is substantiating the demand for reliable dissociation reagents that function seamlessly within complex instrument ecosystems. According to the '2024 State of Tech in Biopharma Report' by Benchling in November 2024, 83% of large biopharmaceutical companies have now automated at least some of their laboratory processes, highlighting the critical operational transition that requires compatible enzymatic solutions.

Simultaneously, there is a distinct expansion of application specifics for organoid dissociation and 3D cell culture, moving beyond traditional monolayer techniques. As researchers prioritize physiologically relevant models for drug screening, the demand is rising for dissociation agents capable of effectively penetrating dense extracellular matrices in spheroids and organoids without compromising cell viability. This technical requirement is pushing the market toward optimized enzymatic solutions tailored specifically for the delicate disaggregation of three-dimensional tissue structures. Highlighting this focus on advanced models, the Sinai Health institute announced in a March 2024 press release that it secured a $10 million investment to establish a state-of-the-art tissue engineering platform dedicated to developing complex human organoids for disease research and drug discovery.

Key Market Players

• Thermo Fisher Scientific Inc
• Lonza Group Ltd
• Merck KGa
• Sartorius AG
• Biosera Europe
• Irvine Scientific
• Chargen Life Sciences LLP
• ScienCell Research Laboratories, Inc.
• STEMCELL Technologies Canada Inc.
• PromoCell GmbH

Report Scope

In this report, the Global Trypsin-EDTA Solution for Cell Dissociation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Trypsin-EDTA Solution for Cell Dissociation Market, By Type

• 0.25% Solution
• 0.05% Solution

Trypsin-EDTA Solution for Cell Dissociation Market, By Application

• Insulin Manufacturing
• Vaccines Manufacturing
• Cell Culture
• Other

Trypsin-EDTA Solution for Cell Dissociation Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Trypsin-EDTA Solution for Cell Dissociation Market.

Available Customizations:

Global Trypsin-EDTA Solution for Cell Dissociation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Trypsin-EDTA Solution for Cell Dissociation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (0.25% Solution, 0.05% Solution)
  • 5.2.2. By Application (Insulin Manufacturing, Vaccines Manufacturing, Cell Culture, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Trypsin-EDTA Solution for Cell Dissociation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Trypsin-EDTA Solution for Cell Dissociation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Trypsin-EDTA Solution for Cell Dissociation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Trypsin-EDTA Solution for Cell Dissociation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Trypsin-EDTA Solution for Cell Dissociation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Trypsin-EDTA Solution for Cell Dissociation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Trypsin-EDTA Solution for Cell Dissociation Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Lonza Group Ltd
• 15.3. Merck KGa
• 15.4. Sartorius AG
• 15.5. Biosera Europe
• 15.6. Irvine Scientific
• 15.7. Chargen Life Sciences LLP
• 15.8. ScienCell Research Laboratories, Inc.
• 15.9. STEMCELL Technologies Canada Inc.
• 15.10. PromoCell GmbH

16. Strategic Recommendations

17. About Us & Disclaimer